The hedgehog (Hh) signaling pathway regulates progenitor cells during embryogenesis and tumorigenesis in multiple organ systems. We have investigated the activity of this pathway in adult gliomas, and demonstrate that the Hh pathway is operational and activated within grade II and III gliomas, but not grade IV de novo glioblastoma multiforme. Furthermore, our studies reveal that pathway activity and responsiveness is confined to progenitor cells within these tumors. Additionally, we demonstrate that Hh signaling in glioma progenitor cells is liganddependent and provide evidence documenting the in vivo source of Sonic hedgehog protein. These findings suggest a regulatory role for the Hh pathway in progenitor cells within grade II and III gliomas, and the potential clinical utility of monitoring and targeting this pathway in these primary brain tumors.
Introduction
Gliomas are the most common primary brain tumors and are divided into four clinical grades. World Health Organization (WHO) grades II-IV are intractable to current therapies and the 5-year survival rate is 33% (American Cancer Society, 2004) . Recently, progenitor or stem-like cells have been isolated from primary brain tumors (Hemmati et al., 2003; Singh et al., 2003 Singh et al., , 2004b Galli et al., 2004; Lee et al., 2006) , and termed 'cancer stem cells' (CSC) (Singh et al., 2004a) . The CSC hypothesis suggests that stem cells constitute a small fraction of the tumor and give rise to partially or fully differentiated cell types comprising the majority of the tumor. The activation and operational status of signaling pathways in brain tumor CSC remain unknown, and their identification and characterization could yield critical targets for new therapeutic avenues. One such mechanism may be the Hedgehog (Hh) pathway, whose activity is required for the growth and maintenance of tumors of the cerebellum, skin, lung, foregut and prostate (Beachy et al., 2004) . The Hh pathway regulates progenitor cell proliferation within these tissues, and in this context, its activity has been linked to tumorigenesis.
Prior reports concerning Hh signaling and gliomas have yielded conflicting results (Dahmane et al., 2001; Katayama et al., 2002) , and thus the operational status of the pathway in gliomas remains to be determined. Prompted by a requirement for Hh signaling in the regulation of cerebral neural progenitor cells (Lai et al., 2003; Ahn and Joyner, 2005) , we investigated the activity of this pathway in gliomas. Our studies indicate that the Hh pathway is activated within a significant portion of grade II (GII) and grade III (GIII) gliomas, but not in grade IV (GIV) de novo glioblastoma multiforme (GBM). We provide evidence that the pathway is activated within tumor cells that express the proliferation marker Ki67 and progenitor cellrelated proteins Bmi-1 and Olig2. In primary glioma cell lines, we demonstrate that Hh pathway activity is ligand-dependent and that pathway responsiveness can be measured under culture conditions that favor progenitor cell maintenance but not differentiation. Taken together, these mechanistic data provide evidence that the Hh pathway is activated in progenitor cells within GII and GIII gliomas, and support a role for Hh signaling in these tumors.
Results

Characterization of Patched protein expression in gliomas
To identify Hh-responsive cells in gliomas, we assayed for expression of the Hh receptor Patched (PTCH; Figure 1 ). Immunohistochemical staining of 13 gliomas revealed scattered PTCH-positive cells within three GII oligodendrogliomas, one GII astrocytoma and three GIII anaplastic astrocytomas, but not in any of three GIV de novo GBM (Figure 2d-l and Supplementary Figure 1A and C). Rare PTCH-positive cells could be seen in only one of three pilocytic astrocytomas . Histopathological examination revealed anisokaryosis within PTCH-expressing cells, indicating their malignant phenotype. PTCH protein expression in GII and GIII gliomas was further corroborated by Western immunoblot (Figure 2m , lanes 3-6). Conversely, PTCH protein expression was lower in GI and GIV gliomas ( Figure 2m , lanes 1, 2, 7 and 8).
The expression of PTCH within a subset of tumor cells suggests that Hh pathway activity may be confined to a specific population of glioma cell types. To characterize PTCH-expressing cells, we analysed a GII astrocytoma for coexpression of the proliferation marker Ki67 (Figure 3a and b) and the stem cell-related marker Bmi-1 (Figure 3c and d) . By sequential doubleantibody labeling, PTCH expression was detected in 23.170.5% of the cells (n ¼ 13 high-powered microscopic fields; average7s.e.m.). Ki67 staining was observed only in PTCH-expressing cells and was coexpressed in 9.370.5% of the PTCH-positive cells (n ¼ 8). Bmi-1 was coexpressed in 87.372.4% of PTCHpositive cells (n ¼ 5). These findings suggest that proliferation is confined to PTCH-expressing cells with progenitor features.
PTCH expression is significantly elevated within GII and GIII gliomas To quantify the differences observed by Western blot analysis of PTCH protein expression in eight gliomas of varying grades, we measured PTCH mRNA levels in these ( Figure 2m ) and 50 other primary brain tumors (Table 1) . As PTCH is a transcriptional target of the Hh pathway (Figure 1) , quantitative real-time-polymerase chain reaction (QRT-PCR) measurement of PTCH mRNA levels provides a sensitive method for assessing the degree of Hh pathway activity in tumor-derived tissues and cell cultures Karhadkar et al., 2004) . For all samples, PTCH levels were normalized to endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels and expressed as the fold-difference relative to a control temporal lobe sample resected from a patient with epilepsy (sample 1 in Table 1 ). In contrast to control samples, the relative PTCH mRNA levels were 2.0970.64 in GI (P ¼ 0.346), 6.6671.31 in GII (P ¼ 0.002), 9.2673.09 in GIII (P ¼ 0.003) and 1.1570.18 in GIV (P ¼ 0.808) gliomas (average7s.e.m.), indicating significant elevation of PTCH mRNA levels only within GII (n ¼ 12) and GIII (n ¼ 12) gliomas. With the exception of a medulloblastoma, low PTCH levels were measured in the other primary brain tumors (samples 56-62 in Table 1 ), and these were not included in our statistical analyses. Within GII and GIII tumors, elevated PTCH expression was detected in oligodendrogliomas and astrocytomas (Table 1 and Figure 4 ). The variability of PTCH levels in GII and GIII glioma samples may indicate that the Hh pathway is activated only in a subset of these tumors, or reflect inherent limitations of the sampling method (see Materials and methods section).
Notably, 21 of the 22 GBM samples in this analysis were clinically de novo, and low PTCH levels in these tumors suggest the following possibilities: (i) the Hh pathway might be activated in de novo GBM as a consequence of PTCH inactivation, (ii) PTCH expression in a CSC population represents a small, and therefore, difficult to measure portion of GBM, or (iii) the pathway is not activated in de novo GBM. To test the first possibility, we measured expression of the Hh gene-target GLI1 (Figure 1 ) by QRT-PCR in an additional set of tissues (Supplementary Figure 2, . In all 11 de novo GBM samples analysed, GLI1 levels were uniformly low and not elevated above those found in control samples. These data suggest that the Hh pathway is not activated within de novo GBM by loss of PTCH-mediated suppression, and that while GLI1 and PTCH transcripts can be detected in GBM (Dahmane et al., 2001) , by quantitative measurement their expression levels are low (Katayama et al., 2002) .
Hh pathway responsiveness is maintained in primary progenitor cells cultured from GII and GIII gliomas To assess the operational status of the Hh pathway in GII-GIV gliomas, primary cell cultures were generated from freshly resected brain tumors. To obtain standard . Secondary and tertiary spheres were generated from dissociated GII and GIII GS plated at clonal density (data not shown). However, serial passage of bulk cultures did not produce expanding cell numbers. In contrast to the exponential growth reported for GS from GBM (Galli et al., 2004; Lee et al., 2006) , the failure to generate long-term GS cultures from GII and GIII gliomas may represent the requirement for alternative culture methods or reflect differences in growth kinetics.
To directly assay Hh pathway activity in these primary glioma cell lines, PTCH and GLI1 mRNA levels were measured following culture in the presence or absence of purified Shh protein (ShhNp) (Taipale et al., 2000) , or cyclopamine, a specific inhibitor of Hh signaling ( Figure 1 ) (Cooper et al., 1998; Chen et al., 2002a) . The addition of ShhNp resulted in elevations of both PTCH and GLI1 expression in short-term GS cultures derived from GII and GIII astrocytomas and oligodendrogliomas, but not from any of the GBM or an anaplastic ependymoma (Figure 5a ). Conversely, treatment of GS with cyclopamine did not reduce PTCH or GLI mRNA. Additionally, pathway responsiveness to ShhNp was absent in standard serum-containing primary glioma cultures (Supplementary Figure 4 and data not shown). These findings provide evidence that the Hh pathway is operationally intact within GII and GIII oligodendrogliomas and astrocytomas under culture conditions that favor progenitor cell maintenance, but not differentiation. 
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Our results indicate that the Hh pathway is at a basal level in GII and GIII GS and that exogenous ligand is required to activate signaling. To further confirm the ability to modulate Hh signaling in GS, we sought to establish whether, once activated, the pathway could then be inhibited. For this purpose, additional GS from a GII astrocytoma and a GIII anaplastic oligodendroglioma were generated in the presence or absence of a Smoothened (SMOH) agonist (SAG; see Figure 1 ) (Chen et al., 2002b; Frank-Kamenetsky et al., 2002) . After 7 days, GS from the corresponding parent culture were re-plated either alone in the presence of SANT1 (a SMOH antagonist; see Figure 1 ) (Chen et al., 2002a) or in increasing doses of SAG. PTCH and GLI1 levels in GS derived from parent cultures grown in the absence of SAG were not further suppressed with SANT1 and demonstrated dose-responsive elevations with SAG ( Figure 5b) . Conversely, PTCH and GLI1 levels were elevated in GS from parent cultures derived in the presence of SAG, and could be reduced to basal levels by SANT1 treatment. These data demonstrate that Hh signaling in GII and GIII GS can be modulated by either activation or inhibition, thereby confirming the operational status of the pathway in these tumors.
On the basis of our survey of 12 GII-GIV GS, we find that the ability to modulate a Hh pathway response in cell lines derived from oligodendroglial and astrocytic GII and GIII tumors, but not from GBM or an ependymoma, correlates well with our PTCH and GLI1 mRNA measurements in gliomas (Table 1, Figure 4 and Supplementary Figure 2) . Furthermore, the inability to modulate basal PTCH and GLI1 levels in GBM GS with cyclopamine, SANT1, ShhNp or SAG (Figure 5a and b) suggests that the Hh pathway is unlikely to be activated or operationally intact in a CSC population within de novo GBM.
PTCH expression is found in an Olig2-positive glial fibrillary acidic protein (GFAP)-negative cell population common to GII and GIII oligodendrogliomas and astrocytomas, but not GBM. The heterogeneity of astrocytic and oligodendroglial tumor cells within diffuse gliomas is well recognized, and their classification is based on the proportion and spatial clustering of these two phenotypic populations. For example, as in our study, tumors may be classified as astrocytoma when the two populations are intermingled with astrocytic predominance, and as oligoastrocytoma when the two populations are separated into distinct areas (Kleihues et al., 1995) . These two cell types have been shown to display mutually exclusive expression of Olig transcription factors and glial fibrillary acidic protein (GFAP) (Azzarelli et al., 2004; Mokhtari et al., 2005) . Therefore, to evaluate in which cellular components the Hh pathway might be activated, we analysed PTCH expression in conjunction with that of Olig2 and GFAP. Within oligodendrogliomas and astrocytomas, PTCH expression was most readily detected within a subset of Olig2-positive and GFAPnegative cells (Figure 6a-d) . However, PTCH expression was not confined to this population, as we also observed PTCH-positive Olig2-negative GFAP-negative cells within the same oligodendroglioma and astrocytoma samples (Figure 6e-h) . Notably, we did not observe PTCH expression in GFAP-positive cells (Figure 6i and j). Rare Olig-2-positive GFAP-negative cells could be identified in de novo GBM, and these cells did not 
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Figure 4 PTCH mRNA expression in gliomas. Graphic illustration of the relative PTCH expression levels from samples listed in Table 1 revealed significant elevation within GII and GIII gliomas only (see text for statistical analyses). Also shown are PTCH levels and corresponding Shh-reporter activity (104-fold with maximal stimulation) in NIH3T3 cells induced with serial dilutions of Shh-CM.
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express PTCH (Figure 6k and l). These findings suggest that the Hh pathway may be activated within a shared population of Olig2-positive GFAP-negative cells in GII and GIII oligodendrogliomas and astrocytomas.
Characterization of Shh expression in gliomas
The induction of PTCH and GLI1 in GII and GIII GS by ShhNp is consistent with a mechanism of liganddependent Hh pathway activation. To determine the source of Hh ligand in gliomas, we assayed for Sonic, Indian and Desert Hh expression in GS. Shh transcript could be detected in one GIII and two GIV GS (Figure 7a ), demonstrating no correlation between Shh expression and pathway responsiveness ( Figure 5 ). These data are consistent with our observations that the pathway is not inhibited by cyclopamine or SANT1 treatment and that exogenous Shh ligand or SAG are required to obtain a Hh response in GS ( Figure 5 ). Corroborating these results, immunohistochemical staining for Shh in GII-GIV gliomas revealed no discernable staining within tumor cells (Figure 7b-d) . II  II  III  IV  IV  IV  IV  III  A  O  A  AA  GBM  GBM  GBM  GBM  AE   PTCH   GLI1 Relative mRNA Levels Characterization of Hh pathway responsiveness in glioma spheres (GS). (a) GS from two astrocytomas (BT18 and BT20), one oligodendroglioma (BT14), one anaplastic astrocytoma (BT29), four GBM (BT44, BT45, BT51 and BT52) and an anaplastic ependymoma (BT60) were cultured for 36 h either alone (control), with 5 mM cyclopamine or 5 nM ShhNp. In triplicate cultures for each cell line and culture condition, PTCH and GLI1 levels were normalized to GAPDH and expressed relative to the untreated control GS. For BT14, cDNAs from triplicate samples were pooled to measure relative GLI1 values due to insufficient starting material. (b) GS from a GII astrocytoma (BT78), a GIII anaplastic oligodendroglioma (BT66) and a GBM (BT79) were generated in the presence or absence of SAG, removed from the corresponding parent culture and subsequently cultured either alone, in the presence of SANT1 or increasing doses of SAG. PTCH and GLI1 levels are expressed relative to GAPDH. A, astrocytoma; O, oligodendroglioma,; AO, anaplastic oligodendroglioma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; AE, anaplastic ependymoma. 
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However, Shh staining was observed at the tumor margin in parenchymal cells with neuronal morphology adjacent to clusters of invading tumor cells (Supplementary Figure 5 ) and within the tumor in cells with prominent nucleoli and the appearance of overrun neurons (Figure 7b-d) . To better determine the cellular source of secreted ligand, we performed in situ hybridization with an Shh RNA probe. Signal was detected only in cells that expressed the neuronal marker NeuN (Figure 7e-g ). These findings suggest that neurons may serve as an in vivo source of Shh ligand.
Discussion
Our studies define the glioma subtypes in which the Hh pathway is activated, namely WHO grades II and III astrocytomas and oligodendrogliomas. We have explored the culture conditions under which pathway modulation can be achieved, and demonstrate that the pathway is not operational in standard serum-containing cultures that induce cell differentiation, but rather in cultures that maintain glioma progenitor cells. Finally, we provide evidence that the Hh pathway is activated in a ligand-dependent manner, with a strict requirement for exogenous ligand. The cellular origin of gliomas is unknown, and in this context it remains to be determined whether the striking absence of Hh pathway activity in the clinically de novo GBMs we analysed indicates that many GII and GIII gliomas may arise from Hh-responsive cell types whereas de novo GBM do not. This concept is reinforced by our observation that GIV GS expressed CD133, a stem cell marker used to identify CSC in GBM (Singh et al., 2003 (Singh et al., , 2004b Bao et al., 2006) , and did not demonstrate Hh pathway modulability, whereas GII and GIII GS were CD133-negative and Hh-responsive (data not shown). The WHO classification of malignant gliomas is based on histological appearance and malignancy grade, with a spectrum of progression of oligodendroglioma (GII) to anaplastic oligodendroglioma (GIII) and of diffuse astrocytoma (GII) to anaplastic astrocytoma (GIII) and GBM (GIV) (Kleihues et al., 2002) . Two clinical GBM entities have been defined, primary or de novo GBM, occurring without evidence of antecedent disease, and secondary GBM, resulting from progression of a previously diagnosed lower grade glioma. Molecular analysis supports the divergent evolution of de novo and secondary GBM subtypes (Ohgaki et al., 2004; Maher et al., 2006) . Our data raise the possibility that the Hh pathway might be activated in secondary GBM. However, we were unable to address this issue as our series contained only one secondary GBM. Nonetheless, our determination that the Hh pathway is activated within GII and GIII gliomas, but not in de novo GBM represents an important distinction for the formulation of clinical studies to investigate the use of Hh modulators as therapeutic agents. This is an important aspect of our findings as earlier work reporting the detection of PTCH and GLI transcripts in GBM tumor samples and standard glioma cell lines by nonquantitative methods (Dahmane et al., 2001) has formed the basis for advocating the clinical testing of Hh inhibitors in patients with GBM (Sanai et al., 2005) .
Our demonstration of Hh-pathway responsiveness in both oligodendrogliomas and astrocytomas, is attributable in part, to the presence of PTCH expression in an Olig2-positive GFAP-negative cell population identified as common to classic oligodendrogliomas, pure astrocytomas and oligoastrocytomas (Mokhtari et al., 2005) . However, our identification of PTCH expression in Olig2-negative GFAP-negative cells suggests that Hh pathway activity may not be exclusive to an oligodendroglial compartment in these tumors. The absence of PTCH staining in GFAP-positive cells indicates that Hh pathway activity may not be present within later stages of astrocytic differentiation, and further lineage marker analysis will be required to assess its presence within astrocytic precursors.
The strict requirement for Hh ligand or agonist to activate the pathway in cell culture, the lack of correlation between Hh ligand expression and pathway-responsive in GS, and the neuronal expression of Shh are consistent with a mechanism of liganddependent pathway activation in GII and GIII gliomas. This is distinct from both the ligand-independent activation in medulloblastoma and the ligand-dependent mechanism identified in lung (Watkins et al., 2003) , foregut and metastatic prostate (Fan et al., 2004; Karhadkar et al., 2004; Sanchez et al., 2004) tumors. Studies from these latter tumor types demonstrate endogenous Shh ligand production in tumor cells Watkins et al., 2003; Fan et al., 2004; Karhadkar et al., 2004; Sanchez et al., 2004) . In contrast, our findings indicate the need for exogenous ligand to activate the pathway. This is an important mechanistic concept for future studies to determine the functional role of Hh signaling in gliomas.
Hh pathway activity is known to contribute to the growth and maintenance of multiple tumor types (Beachy et al., 2004) . Although functional roles for Hh signaling in GII and GIII gliomas are yet to be determined, this study does provide relevant observations. For example, we report that the pathway is activated in glioma cells with proliferative and progenitor cell features, and that tumor cells can be visualized clustered around Shhexpressing cells at the tumor margin. These findings suggest that Hh signaling may regulate glioma cell growth and invasion. Furthermore, given the known role of Shh signaling in initiating Olig2-mediated oligodendrogliogenesis during embryonic development , our data suggest an analogous function in GII and GIII gliomagenesis. As such, our findings point to the potential clinical utility of monitoring and targeting the Hh pathway in GII and GIII gliomas.
Materials and methods
Tissue procurement
Brain tissues were obtained at Vanderbilt Medical Center in accordance with an institutional review board approved protocol. A portion of each tumor was sent to pathology for diagnoses and remaining tissue to a tumor bank for analyses. Primary brain tumors were phenotyped and graded as described (Kleihues et al., 1995 (Kleihues et al., , 2002 .
Immunohistochemical analysis of tumors
Immunodetection was performed with the following antibodies: PTCH-1 (1:200; Santa Cruz Biotechnologies, Santa Cruz, CA, USA, G19 Lot No. J2505), Shh (1:200; Santa Cruz Biotechnologies, H160), Ki67 (1:10; Chemicon, Temecula, CA, USA), Bmi-1 (1:50; Serological Corporations, Billerica, MA, USA), Olig2 (1:250; Chemicon), GFAP (1:1000; Chemicon) and NeuN (1:500; Chemicon). Sequential double-antibodylabeling was performed as described (Becher et al., 1998) . In situ hybridization for Shh was performed as described (Oh et al., 2005) , with digoxigenin-labeled riboprobe synthesized from Shh cDNA (forward 5 0 -GCGGCACCAAGCTGG TGAAG-3 0 and reverse 5 0 -GGTGAGCAGCAGGCGCT CGC-3 0 ).
Western immunoblot analysis of tumors PTCH (G19, 1:200) or human a-actinin (1:200; Chemicon) immunoblotting in snap-frozen tumor samples was performed as described (Chen et al., 2002a) .
RNA extraction, cDNA synthesis and QRT-PCR See Supplementary methods.
Primary glioma-derived cell culture See Supplementary methods.
Reverse transcriptase (RT)-PCR cDNA was amplified with intron-spanning primers specific for nestin, Bmi-1, Musashi-1, Sox-2, CD133 and GAPDH (Supplementary Table 1 ) for 40 PCR cycles and visualized in 2% agarose/TAE gels stained with ethidium bromide. The identity of each amplification product was confirmed by sequencing.
Hh-signaling assays in primary glioma cell cultures Standard cell lines or GS were cultured in triplicate for 36-42 h either alone, with 5 mM cyclopamine, 100 nM SANT1, 5 nM ShhNp (purified, fully lipid-modified Shh protein) (Taipale et al., 2000) or varying doses (5-500 nM) of SAG. Confluent standard cell lines were cultured in Dulbecco's modified Eagle's medium/F12 with 0.5% fetal bovine serum and GS in neurobasal medium with B-27 supplement, 2 mg/ml heparin, 2 mM L-Gln, 20 ng/ml LIF, 20 ng/ml EGF, and 20 ng/ml FGFb. PTCH, GLI1 and GAPDH levels were measured by QRT-PCR as described above.
